Service Line:+86-022-82164980
Address:FL-4, Building A5, International Enterprise Community, Tianjin, China
Email:[email protected]
Catalog Number | KMP2421 |
---|---|
Product Name | Human CD274 Protein, Fc Tag |
Product Description | The Human CD274 Protein(KMP2421) is produced in HEK293 Cells and the target gene encoding Phe19-Thr239 is expressed with a Fc tag at the C-terminus. |
Molecular Weight | 25.3 kDa |
Alias | programmed cell death 1 ligand 1, CD274 |
Species | Human |
Host | HEK293 Cells |
Size | 50ug, 100ug, 200ug |
Purification | Affinity purification |
Purity | >95% as determined by SDS-PAGE |
Endotoxin | <1.0 EU/ug determined by the LAL method |
Buffer | 20mM PB, 150mM NaCl, pH7.4 |
Uniprot | Q8IZR5 |
SDS-PAGE | ![]() |
Function | Acts as a backup for CMTM6 to regulate plasma membrane expression of PD-L1/CD274, an immune inhibitory ligand critical for immune tolerance to self and antitumor immunity. May protect PD-L1/CD274 from being polyubiquitinated and targeted for degradation. |
Background | CD274, also known as B7-H1 or programmed death ligand 1(PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1(PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. |
Storage | Aliquot and store at -20℃ to -80℃. Avoid repeated freezing and thawing cycles. |
Note | This product is for research use only. |
References | Nature 549:106-110 (2017) |